Muhammad Haris Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muhammad Haris Khan has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Abdur Rehman
Department of medicine, Saidu Medical College, Swat, Pakistan
1 shared publication Ahmed Jamal Chaudhary
Internal Medicine, Michigan State University, Detroit, USA
1 shared publication- Aleena Amir Malik
Department of Medicine, United Medical and Dental College, Karachi, Pakistan
1 shared publication Ali Nawaz
Department of Medicine, Lady Reading Hospital, Peshawar, Pakistan
1 shared publicationAli Raza
11 Cardiology, Khyber Teaching Hospital, Medical Teaching Institution (MTI), Peshawar, PAK
1 shared publication- Anfal Khan
Saidu Medical College, Swat, Pakistan
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
Clinical outcomes of impella compared with intra-aortic balloon pump support in cardiogenic shock: a systematic review and meta-analysis
- 10 September 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
Open AccessClinical outcomes of impella compared with intra-aortic balloon pump support in cardiogenic shock: a systematic review and meta-analysis
- Open Access
- 28 July 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5327-5338
Efficacy of simvastatin as adjunctive therapy in liver cirrhosis: an updated meta-analysis of randomized controlled trials
The clinical benefit of simvastatin as an adjunctive treatment in liver cirrhosis remains inconclusive, with prior syntheses becoming outdated after the publication of the largest trial on the topic. This updated meta-analysis aimed to evaluate the therapeutic impact of simvastatin in cirrhotic patients. A systematic search was conducted in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov using MeSH terms related to “Simvastatin” and “Liver Cirrhosis.” Randomized controlled trials (RCTs) comparing simvastatin to placebo or any other drugs were included. Nine RCTs, including 966 patients, were analyzed. Simvastatin showed no statistically significant effect on all-cause mortality, although a borderline trend toward a 37% relative risk reduction was observed [risk ratio (RR): 0.63; 95% confidence interval (CI): 0.38–1.04; P = 0.07], suggesting a potentially clinically meaningful effect. No significant differences were found in bleeding (RR: 0.70; 95% CI: 0.45–1.08), development of ascites (RR: 0.91; 95% CI: 0.69–1.21), hepatorenal syndrome (RR: 0.85; 95% CI: 0.64–1.87), hepatic venous pressure gradient (standardized mean difference [SMD]: −0.19; 95% CI: −0.49 to 0.11), wedged hepatic venous pressure (SMD: −0.11; 95% CI: −0.44 to 0.23), free hepatic venous pressure (SMD: 0.04; 95% CI: −0.21 to 0.29), and adverse events (RR: 1.04; 95% CI: 0.95–1.15), serious adverse events (RR: 0.93; 95% CI: 0.75–1.15), and musculoskeletal adverse events (RR: 1.27; 95% CI: 0.87–1.85). Overall, simvastatin did not demonstrate statistically significant reductions in cirrhosis-related complications. Nevertheless, the observed trend toward lower mortality suggests a possible protective effect that existing trials may be underpowered to confirm. Larger, well-designed RCTs are warranted to clarify its impact on survival outcomes.
- 28 July 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5327-5338
Open AccessEfficacy of simvastatin as adjunctive therapy in liver cirrhosis: an updated meta-analysis of randomized controlled trials
The clinical benefit of simvastatin as an adjunctive treatment in liver cirrhosis remains inconclusive, with prior syntheses becoming outdated after the publication of the largest trial on the topic. This updated meta-analysis aimed to evaluate the therapeutic impact of simvastatin in cirrhotic patients. A systematic search was conducted in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov using MeSH terms related to “Simvastatin” and “Liver Cirrhosis.” Randomized controlled trials (RCTs) comparing simvastatin to placebo or any other drugs were included. Nine RCTs, including 966 patients, were analyzed. Simvastatin showed no statistically significant effect on all-cause mortality, although a borderline trend toward a 37% relative risk reduction was observed [risk ratio (RR): 0.63; 95% confidence interval (CI): 0.38–1.04; P = 0.07], suggesting a potentially clinically meaningful effect. No significant differences were found in bleeding (RR: 0.70; 95% CI: 0.45–1.08), development of ascites (RR: 0.91; 95% CI: 0.69–1.21), hepatorenal syndrome (RR: 0.85; 95% CI: 0.64–1.87), hepatic venous pressure gradient (standardized mean difference [SMD]: −0.19; 95% CI: −0.49 to 0.11), wedged hepatic venous pressure (SMD: −0.11; 95% CI: −0.44 to 0.23), free hepatic venous pressure (SMD: 0.04; 95% CI: −0.21 to 0.29), and adverse events (RR: 1.04; 95% CI: 0.95–1.15), serious adverse events (RR: 0.93; 95% CI: 0.75–1.15), and musculoskeletal adverse events (RR: 1.27; 95% CI: 0.87–1.85). Overall, simvastatin did not demonstrate statistically significant reductions in cirrhosis-related complications. Nevertheless, the observed trend toward lower mortality suggests a possible protective effect that existing trials may be underpowered to confirm. Larger, well-designed RCTs are warranted to clarify its impact on survival outcomes.
- Open Access
- 30 August 2025
- Published by Springer Nature in Cureus
- Vol. 17 (8)
Hemodynamic Patterns in Septic Cardiomyopathy: Insights From Echocardiographic Parameters and Biomarker Analysis
Introduction Septic cardiomyopathy (SCM) refers to an acute, reversible impairment of cardiac performance. This study aimed to evaluate hemodynamic patterns in SCM using echocardiographic parameters and cardiac biomarkers in critically ill patients. Materials and methods A 12-month prospective observational study was conducted at a single tertiary care center in Peshawar, Pakistan. Adult ICU patients with sepsis or septic shock underwent transthoracic echocardiography (TTE) within 48 hours of admission, with a repeat study on day 5 or earlier if clinically indicated. Left ventricular (LV) and right ventricular (RV) systolic and diastolic functions were assessed, including global longitudinal strain (GLS) and RV free-wall strain. High-sensitivity troponin I (hs-TnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were measured on days 1 and 3. Associations between cardiac dysfunction and in-hospital mortality were analyzed using multivariable logistic regression after adjusting for age, sex, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and vasopressor use. Results Among 122 patients, the prevalence of SCM, defined by LV GLS > −17%, was high, with concurrent RV dysfunction observed in a significant proportion. Elevated hs-TnI and NT-proBNP levels correlated with impaired GLS and adverse outcomes. After multivariable adjustment, GLS impairment and elevated NT-proBNP remained independently associated with in-hospital mortality. Conclusions In this South Asian cohort with sepsis or septic shock, combined strain-based echocardiography and biomarker profiling revealed distinct patterns of myocardial dysfunction associated with early mortality. While these findings highlight the prognostic utility of GLS and NT-proBNP, they should be interpreted as associations rather than causal effects. Larger multicenter studies with extended follow-up and incorporation of additional biomarkers and advanced imaging are needed to validate these observations and clarify underlying pathophysiological mechanisms.
- 30 August 2025
- Published by Springer Nature in Cureus
- Vol. 17 (8)
Open AccessHemodynamic Patterns in Septic Cardiomyopathy: Insights From Echocardiographic Parameters and Biomarker Analysis
Introduction Septic cardiomyopathy (SCM) refers to an acute, reversible impairment of cardiac performance. This study aimed to evaluate hemodynamic patterns in SCM using echocardiographic parameters and cardiac biomarkers in critically ill patients. Materials and methods A 12-month prospective observational study was conducted at a single tertiary care center in Peshawar, Pakistan. Adult ICU patients with sepsis or septic shock underwent transthoracic echocardiography (TTE) within 48 hours of admission, with a repeat study on day 5 or earlier if clinically indicated. Left ventricular (LV) and right ventricular (RV) systolic and diastolic functions were assessed, including global longitudinal strain (GLS) and RV free-wall strain. High-sensitivity troponin I (hs-TnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were measured on days 1 and 3. Associations between cardiac dysfunction and in-hospital mortality were analyzed using multivariable logistic regression after adjusting for age, sex, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and vasopressor use. Results Among 122 patients, the prevalence of SCM, defined by LV GLS > −17%, was high, with concurrent RV dysfunction observed in a significant proportion. Elevated hs-TnI and NT-proBNP levels correlated with impaired GLS and adverse outcomes. After multivariable adjustment, GLS impairment and elevated NT-proBNP remained independently associated with in-hospital mortality. Conclusions In this South Asian cohort with sepsis or septic shock, combined strain-based echocardiography and biomarker profiling revealed distinct patterns of myocardial dysfunction associated with early mortality. While these findings highlight the prognostic utility of GLS and NT-proBNP, they should be interpreted as associations rather than causal effects. Larger multicenter studies with extended follow-up and incorporation of additional biomarkers and advanced imaging are needed to validate these observations and clarify underlying pathophysiological mechanisms.